The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and
erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal
growth factor receptor (EGFR) have shown activity against solid malignancies when used as …

BACKGROUND: Individualized treatment is an attractive challenge that may allow for more
effective and safer treatment of human disease. Activating mutations in the epidermal growth …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …

Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …

Background: The discovery of mutations in epidermal growth factor receptor (EGFR) has
dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the …

The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations
are sensitive to EGFR tyrosine kinase inhibitors (TKIs), including gefitinib. Acquired …